186 related articles for article (PubMed ID: 35483620)
1. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
Grabner M; Strati E; Sandman K; Forsythe A
J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
[No Abstract] [Full Text] [Related]
4. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
Michonneau D; Quignot N; Jiang H; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):514-525. PubMed ID: 36765178
[TBL] [Abstract][Full Text] [Related]
8. Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes.
Farhadfar N; Leather HL; Wang S; Burton N; IrizarryGatell V; Itzler R; Salloum RG; Wingard JR
Transplant Cell Ther; 2021 Dec; 27(12):1007.e1-1007.e8. PubMed ID: 34537422
[TBL] [Abstract][Full Text] [Related]
9. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
10. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Economic Burden Associated With Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Germany.
Holtick U; Quignot N; Kapso-Kapnang R; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K
Transplant Proc; 2024; 56(1):191-200. PubMed ID: 38199852
[TBL] [Abstract][Full Text] [Related]
12. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis.
Johnson BH; Taylor A; Kim G; Drahos J; Yang J; Akbari M; Shah NN
Biol Blood Marrow Transplant; 2019 Apr; 25(4):834-841. PubMed ID: 30625389
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
16. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Matin A; Smith BH; Mangaonkar A; Duffy DJ; Wolf R; Alkhateeb H; Shah MV; Hogan WJ; Litzow MR
Transplant Cell Ther; 2023 May; 29(5):324.e1-324.e6. PubMed ID: 36682472
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda B; Solana-Altabella A; Cano I; Acuña-Cruz E; Rodríguez-Veiga R; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Gómez I; Solves P; Lorenzo I; Piñana JL; Sanz J; Guerreiro M; Montoro Gómez J; Díaz-González A; Marco J; Blanco A; Sanz MÁ; Montesinos P
J Clin Apher; 2021 Aug; 36(4):612-620. PubMed ID: 33964038
[TBL] [Abstract][Full Text] [Related]
18. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.
Herzog S; Weisdorf DJ; Shanley R; Rayes A; Holtan SG; Young JA; MacMillan ML; El Jurdi N
Blood Adv; 2023 Jul; 7(14):3644-3650. PubMed ID: 37036949
[TBL] [Abstract][Full Text] [Related]
19. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
Holtan SG; Yu J; Paranagama D; Tang J; Choe HK; Naim A; Joachim Deeg H; Galvin J
Bone Marrow Transplant; 2022 Sep; 57(9):1399-1404. PubMed ID: 35739326
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]